Avalo Therapeutics, Inc. (AVTX) · Aug 6, 2026 · Company update

Cash runway reaches 2029, but non-cash charges drive an EPS miss

Cash runway reaches 2029, but non-cash charges drive an EPS miss

The headline earnings result missed the published expectation, but the miss is largely accounting-driven. Avalo reported a $0.83 quarterly loss per share versus a published consensus of roughly a $0.59 loss; there is no meaningful revenue comparison for this clinical-stage company. The gap was driven in part by a $6.6 million fair-value loss on contingent consideration and a $10.0 million abdakibart development milestone, rather than a sudden collapse in the core program. (Income Statement; Financial Highlights)

MetricQ2 2026Q2 2025 / expectation
Net loss$36.4 million$20.8 million (Income Statement)
Basic and diluted EPS$(0.83)$(1.92) prior year; published consensus approximately $(0.59)
R&D expense$23.4 million$14.1 million prior year (Financial Highlights)
G&A expense$8.1 million$5.2 million prior year (Financial Highlights)
Cash, cash equivalents and investments$472.2 million$98.3 million at December 31, 2025 (Financial Highlights; Balance Sheet)
Net cash used in operating activities, six months$37.7 millionNot provided for prior-year comparison (Financial Highlights)
Common shares outstanding, period end52.9 million18.5 million at December 31, 2025 (Balance Sheet)

The more important operating update is funding, not quarterly profitability. Cash, cash equivalents and investments totaled $472.2 million at June 30, and management said that resources should fund operations into 2029. That materially reduces near-term financing pressure, although the balance sheet also shows common shares rising to 52.9 million from 18.5 million at year-end, indicating that part of the strengthened cash position came with substantial equity dilution. (Financial Highlights; Balance Sheet)

The clinical story is supportive but mostly a recap, not a fresh data catalyst in this filing. Avalo reiterated positive Phase 2 LOTUS topline results for abdakibart in hidradenitis suppurativa, the plan to move into a registrational Phase 3 program, and the addition of AVTX-010 with an expected IND filing in the first half of 2027. The filing adds execution plans and capital support, but does not provide new efficacy, safety, enrollment, or Phase 3 timing detail to materially upgrade the clinical outlook. (Business Updates)

Net: the quarter is financially messy but strategically intact. Relative to expectations, the EPS miss is a negative, yet it is softened by non-cash valuation expense and a milestone tied to advancing the lead asset. The long cash runway and Phase 3 readiness offset much of that accounting shortfall, leaving the overall message mixed rather than clearly favorable or unfavorable.

Original filing on SEC EDGAR

More Avalo Therapeutics, Inc. news

Cash runway reaches 2029, but non-cash charges drive an EPS miss | AVTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.